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Purpose: To describe the prevalence, incidence, and progression of retinopathy and to report associations
with demographic, clinical, and biochemical variables in people with diabetes in Southern Malawi.
Design: Prospective cohort study.
Participants: Subjects were systematically sampled from 2 primary care diabetes clinics.
Methods: We performed the ﬁrst prospective cohort study of diabetic retinopathy from Sub-Saharan Africa
over 24 months. Visual acuity, glycemic control, blood pressure, human immunodeﬁciency virus (HIV) status,
urine albumin-to-creatinine ratio, hemoglobin, and lipids were assessed. Retinopathy was graded at an
accredited reading center using modiﬁed Wisconsin grading of 4-ﬁeld mydriatic photographs.
Main Outcome Measures: Incidence of sight-threatening retinopathy and progression of retinopathy by 2
steps on the Liverpool Diabetic Eye Study Scale.
Results: A total of 357 subjects were recruited to the 24-month cohort study. At baseline, 13.4% of subjects
wereHIV positive and 15.1%were anemic. The 2-year incidence of sight-threatening diabetic retinopathy (STDR) for
subjects with level 10 (no retinopathy), level 20 (background), and level 30 (preproliferative) retinopathy at baseline
was 2.7% (95% conﬁdence interval [CI], 0.1e5.3), 27.3% (95% CI, 16.4e38.2), and 25.0% (95% CI, 0e67.4),
respectively. In a multivariate logistic analysis, 2-step progression of diabetic retinopathy was associated with
glycosylated hemoglobin (odds ratio [OR], 1.27; 95% CI, 1.12e1.45), baseline grade of retinopathy (OR, 1.39; 95%
CI, 1.02e1.91), and HIV infection (OR, 0.16; 95% CI, 0.03e0.78). At 2 years, 17 subjects (5.8%) lost 15 letters.
Conclusions: Incidence of STDR was approximately 3 times that reported in recent European studies. The
negative association of HIV infection with retinopathy progression is a new ﬁnding. Ophthalmology 2016;123:1919-
1925ª 2016 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Supplemental material is available at www.aaojournal.org.The International Diabetes Federation has estimated that the
number of adults diagnosed with diabetes in Africa will
increase from 12.1 million in 2010 to 23.9 million in 2030.1
The prevalence and incidence of sight-threatening diabetic
retinopathy (STDR) in developed countries2e4 and the
association with systemic factors, including glycemic
control,5,6 blood pressure,7 and blood lipid levels,8 are well
documented. No cohort studies have investigated the
determinants of severity and progression of diabetic
retinopathy (DR) in Sub-Saharan Africa.9 In this resource-
poor setting, population-speciﬁc variables, such as a high
burden of infectious disease (including human immunode-
ﬁciency virus [HIV] and malaria) and anemia, may affect
the spectrum of pathology encountered.
Malawi (population 15.9 million) is one of the poorest
countries in the world, with an annual per capita health care 2016 The Authors. Published by Elsevier Inc. on behalf of the American Academy
of Ophthalmology. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).expenditure of US$77.10 The World Health Organization
(WHO) Malawi national STEPwise survey estimated a
prevalence of diabetes of 5.6% in adults aged 25 to 64
years, with a similar prevalence in rural and urban areas.11
In 2007, our group performed a cross-sectional study us-
ing clinical ocular examination to assess grades of retinop-
athy in patients attending the diabetes clinic at Queen
Elizabeth Central Hospital (QECH), Blantyre.12,13 We re-
ported a high prevalence of sight-threatening and prolifer-
ative retinopathy: 19.6% and 5.7%, respectively. Because of
these important ﬁndings, we performed the Malawi Diabetic
Retinopathy Study (MDRS), a prospective, observational
cohort study of patients attending 2 hospital diabetes clinics
over 24 months. The study aimed to describe the prevalence,
incidence, and progression of DR in Southern Malawi and
to investigate the determinants of retinopathy severity and1919http://dx.doi.org/10.1016/j.ophtha.2016.05.042
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Ophthalmology Volume 123, Number 9, September 2016progression in this population. Baseline data from the cohort
have been published.14
Methods
Setting
The QECH in Blantyre is the main teaching hospital in Malawi. It
provides primary and secondary care to the urban and semi-urban
population of greater Blantyre (w1.0 million people, 50% adult)
and tertiary care to the southern region. Zomba Central Hospital
(ZCH) provides primary and secondary care to the Zomba district.
The diabetes clinics at QECH and ZCH are the only public sector
diabetes clinics in Blantyre and Zomba, with approximately 2000
and 250 registered patients, respectively. The clinics provide free
consultation and monitoring (measurement of height and weight,
blood pressure, and fasting blood glucose). Medications regularly
available free of charge are metformin, glibenclamide, and
insulin (lente and soluble), as well as a limited range of
antihypertensives.
Participants
Patient selection has been described.14 Brieﬂy, systematic random
sampling was used to select subjects from the diabetes clinics at
QECH and ZCH between December 2011 and May 2012.
Patients attend these clinics for medical management of diabetes;
no eye care is provided. The inclusion criterion was a diagnosis
of diabetes according to American Diabetes Association
criteria.15 Exclusion criteria were age <18 years and diagnosis of
gestational diabetes according to American Diabetes Association
criteria. The diabetes clinics at QECH and ZCH provide
predominantly primary diabetes care (primary care for diabetes is
nonexistent at the health center level). Central hospitals are
tertiary centers that receive referral cases. To effectively exclude
referral cases, patients living more than 60 km from the clinic in
question and those visiting the clinic for the ﬁrst time were
excluded from the study.
Procedures
After assessment at baseline, subjects were recalled (by telephone
or home visit) at 12 and 24 months. Clinical assessment of subjects
in the MDRS has been described.14 Brieﬂy, visual acuity (VA)
(uncorrected and using pinhole) was measured as the number of
letters read on a standard Early Treatment of Diabetic
Retinopathy Study (ETDRS) chart. Moderate visual impairment
(50e59 letters; equivalent to 6/24 Snellen) and severe visual
impairment or blindness (<50 letters; equivalent to 6/36 or
worse) were deﬁned according to the WHO.16 For each patient
with corrected VA <80 letters in the better eye, the primary
cause of visual impairment was recorded by the examining
clinician (P.I.B.). Subjects were classiﬁed as having hypertension
according to the WHO deﬁnition11: taking antihypertensive
medication, systolic blood pressure 140 mmHg, or diastolic
blood pressure 90 mmHg. All subjects were offered point-of-
care testing for HIV (Malawian national protocol17) and
hemoglobin level. Thresholds for anemia were set according to
WHO guidelines: 130 g/l for men and 120 g/l for women.18
Blood samples were assayed for putative biochemical risk
factors: fasting glucose, triglycerides, low-density lipoprotein
cholesterol, high-density lipoprotein cholesterol, serum creatinine,
urine albumin-to-creatinine ratio (uACR), and glycosylated he-
moglobin (HbA1c).
Retinopathy and maculopathy were classiﬁed by feature-
speciﬁc grading using deﬁnitions established in the Liverpool1920Diabetic Eye Study (LDES)19 (Appendix Fig 1, available at
www.aaojournal.org). Dual grading of digital photographic
images of four 45 standard ﬁelds19 was performed by accredited
graders at the Liverpool Reading Centre. Sight-threatening dia-
betic retinopathy was deﬁned as any of the following: moderate
preproliferative retinopathy or worse (level 40 to 71); macular
exudates in a circinate pattern or within 1 disc diameter of the
foveal center or clinically signiﬁcant macular edema (ETDRS
deﬁnition20) (level 3e4: sight-threatening maculopathy); or other
diabetes-related retinal vascular disease: central or branch retinal
artery occlusion, central or branch retinal vein occlusion. Subjects
who met thresholds for scatter or macular laser treatment were
treated by 1 ophthalmologist (P.I.B.). Threshold for scatter laser
treatment was the ETDRS 4-2-1 rule (4 quadrants of hemorrhages/
microaneurysms standard 2A or greater, or 2 quadrants of venous
beading standard 6A or greater, or 1 quadrant of intraretinal
microvascular abnormalities standard 8A or greater). Threshold for
macular laser was clinically signiﬁcant macular edema as deﬁned
in the ETDRS20 and VA less than 85 ETDRS letters. The majority
of deaths in Malawi are not registered. The relatives of deceased
subjects were visited at home by a study nurse to conﬁrm the
death. Death was recorded if conﬁrmed by a ﬁrst-degree relative
or “traditional authority” (village leader in rural districts).
Statistical Analysis
Grades of retinopathy were calculated by patient according to the
worse or only gradable eye. Visual acuity data were investigated by
patient according to the better eye. The primary outcome was
progression of DR by 2 or more steps on the LDES severity scale
(equates to 1-step progression in both eyes or 2-step progression in
1 eye). We constructed a multiple logistic regression model
(backward stepwise with probability of removal of 0.2) to deter-
mine the odds ratio (OR) and 95% conﬁdence intervals (CIs) for 2-
step progression in association with an initial 12 variables: time
since diagnosis of diabetes, type of diabetes, baseline grade of DR,
mean HbA1c (mean of measurement at baseline and 12 and 24
months), systolic blood pressure, uACR, hemoglobin, high-density
lipoprotein cholesterol, triglycerides, HIV status, age, and scatter
laser treatment any time between baseline and 24 months.
Descriptive analysis showed that uACR did not demonstrate a
linear association with probability of a 2-step progression; a log-
arithmic transformation (base 10) was more suitable. All tests were
2 sided, and a P value <0.05 was taken to indicate statistical
signiﬁcance. All calculations were performed using STATA
version 12 (StataCorp LP, College Station, TX). The study was
approved by the University of Liverpool Research Ethics Com-
mittee and the University of Malawi College of Medicine Research
Ethics Committee. All participants gave written informed consent.Results
Of 357 subjects recruited, 322 were seen for at least 1 further study
visit and are included in the progression analysis. A total of 313
subjects (88%) and 295 subjects (83%) were assessed at 12 and 24
months, respectively (Appendix Fig 2, available at
www.aaojournal.org). Median time to follow-up was 2.0 years
(interquartile range, 1.9e2.1 years). Baseline characteristics of
subjects seen at 24 months and those who were not seen are shown
in Table 1. A total of 50 subjects (14.0%) were HIV positive (48 at
baseline and 2 new diagnoses during the study). Incidence of death
in the MDRS cohort at 24 months was 8.0% (95% CI, 5.1e10.9;
n ¼ 357; Life Table method). Incidence of death among HIV-
positive subjects was 18.1% (95% CI, 7.4e28.8; n ¼ 50). Death
during the MDRS was associated with STDR (OR, 2.51; 95% CI,
Table 1. Baseline Demographic, Clinical, and Biochemical Measurements and Retinopathy Grading for 357 Subjects in the Malawi
Diabetic Retinopathy 24-Month Cohort Study Categorized by Follow-up: Traced and Assessed at 24 Months (n ¼ 295) or Not Seen at 24
Months (n ¼ 62)
Baseline Characteristic
Subjects Seen at 24 Months
(n [ 295)
Subjects Not Seen at 24 Months
(n [ 62) P Value
Age (yrs), median (IQR) 53.5 (43.4e60.2) 56.2 (48.7e66.0) 0.04*,y
Female sex, n (%) 180 (61.0) 36 (58.1) 0.67z
Type 1 diabetes, n (%) 29 (9.8) 6 (9.7) 0.99z
Duration (yrs), median (IQR) 4.1 (1.9e8.1) 4.5 (2.1e8.1) 0.58x
sBP (mmHg), median (IQR) 135 (121e156) 134 (118e159) 0.93y
HbA1c (NGSP %), mean (SD) 7.8 (2.4) 8.0 (3.1) 0.57y
Hb (g/dl), mean (SD) 14.1 (1.8) 13.0 (2.2) 0.0001*,y
HIV positive, n (%) 36 (12.2) 12 (19.4) 0.15z
LDL cholesterol (mmol/l), mean (SD) 2.49 (0.93) 2.18 (0.99) 0.019*,y
Increased uACR (M >2.5; F >3.5 mg/mmol), n (%) 91 (30.8) 31 (50) 0.005*,z
Any DR, n (%; 95% CI) 154 (52.2; 46.5e57.9) 25 (40.3; 28.1e52.5) 0.09z
STDR, n (%; 95% CI) 88 (29.8; 24.6e35.0) 17 (27.0; 16.0e38.1) 0.76z
Proliferative DR, n (%; 95% CI) 16 (5.4; 2.8e8.0) 10 (16.1; 7.0e25.3) 0.007*,z
CI ¼ conﬁdence interval; DR ¼ diabetic retinopathy; Hb ¼ hemoglobin; HbA1c ¼ glycosylated hemoglobin; HIV ¼ human immunodeﬁciency virus;
IQR ¼ interquartile range; LDL ¼ low-density lipoprotein; NGSP ¼ National Glycohemoglobin Standardisation Program; sBP ¼ systolic blood pressure;
SD ¼ standard deviation; STDR ¼ sight-threatening diabetic retinopathy; uACR ¼ urine albumin-to-creatinine ratio.
*Indicates statistical signiﬁcance.
yUnpaired t test.
zFisher exact test.
xWilcoxon rank sum test.
Burgess et al  Diabetic Retinopathy in Sub-Saharan Africa1.15e5.48; P ¼ 0.02; univariate analysis), proliferative DR (PDR;
OR, 6.47; 95% CI, 2.51e16.7; P ¼ 0.0001), HIV (OR, 3.72; 95%
CI, 1.54e9.00; P ¼ 0.003), and moderate visual impairment (OR,
8.21; 95% CI, 2.48e27.1; P ¼ 0.001). Two (or more) step pro-
gression (from baseline) was observed at 12 or 24 months in 69
subjects (OR, 21.4%; 95% CI 16.9e25.9); 3 (or more) step pro-
gression was observed in 30 subjects (OR, 9.3%; 95% CI,
6.1e12.5) (this analysis includes both subjects with no retinopathy
and those with retinopathy at baseline). Of 225 subjects without
STDR at baseline, 23 (OR, 10.2%; 95% CI, 6.3e14.2) developed
the condition during the study (Table 2; Appendix Tables 1e3,
available at www.aaojournal.org; Fig 1). Of 26 subjects with
level 60 DR or more at baseline, at 24 months the following
grades of DR were recorded: 7 subjects with level <60, 4
subjects with level 60, and 5 subjects with level >60. Eight
subjects died, and 2 subjects were lost to follow-up. Appendix
Table 4 (available at www.aaojournal.org) details the number of
subjects who were listed for, started, and completed a course of
laser treatment during the course of the MDRS.
In univariate analysis, 2-step progression of retinopathy was
positively associated with duration of diabetes, baseline grade of
DR, scatter laser treatment, HbA1c, and uACR and negatively
associated with HIV infection. Higher mean HbA1c and higher
baseline grade of retinopathy were risk factors for 2-step progres-
sion in multivariate analysis. Human immunodeﬁciency virus
infection was negatively associated with progression of DR
(Table 3). This association may have been inﬂuenced by the high
mortality among subjects with HIV and diabetes. Therefore, we
performed a sensitivity analysis. The univariate association of
HIV infection with a composite variable of 2-step progression at
24 months or death during the study was not statistically signiﬁcant
(OR, 0.84; 95% CI, 0.41e1.75; P ¼ 0.64). Human immunodeﬁ-
ciency virus was not selected by a stepwise procedure for a mul-
tiple logistic regression model with the composite term as the
dependent variable (data not shown).
A total of 127 subjects (43.0%) lost 5 ETDRS letters over the
course of the study, of whom 17 (5.8%) lost 15 letters. The mostcommon primary causes of visual loss for the 127 subjects who lost
5 letters were DR (38.6%), cataract (16.5%), and both DR and
cataract (3.9%). Incidence at 24 months of developing moderate
visual impairment (50e59 letters; equivalent to 6/24 Snellen) or
severe visual impairment or blindness (<50 letters; equivalent to 6/
36 or worse) was 0.9% (0e2.0) and 1.5% (0.2e2.8), respectively
(Life Table method; n ¼ 322).Discussion
We report the ﬁrst prospective longitudinal study of DR
from sub-Saharan Africa. Incidence at 24 months of any DR
(new DR) was 38.0%. Incidence of STDR for those with no
(level 10), background (level 20), and mild preproliferative
(level 30) retinopathy at baseline was 2.7%, 27.3%, and
25.0%, respectively. Higher HbA1c and higher baseline
grade of DR were risk factors for progression of retinopathy
in multivariate analysis. HIV was negatively associated with
progression. Despite the availability of laser treatment, 17
subjects (5.8%) had moderate visual loss (lost 15 letters)
during the 2 years of the study.
Few high-quality cohort studies are available for com-
parison from the African or Asian continents. In Mauritius,
researchers followed up a population-based study performed
in 199221 with a survey of diabetes complications in 1998.22
The 6-year incidence of DR and PDR among subjects with
diabetes but no DR in the ﬁrst survey was 23.8% and 0.4%,
respectively. The 6-year incidence of PDR among subjects
with mild nonproliferative DR (equivalent to level 20 in
LDES grading) and moderate nonproliferative DR (equiv-
alent to LDES level 30 or level 40) was 5.2% and 29.4%,
respectively. Compared with recent studies of European
screening programs, in the MDRS, 2-year progression to1921
Table 2. Life Tables Showing Cumulative Yearly Incidence of Development of Grades of Retinopathy and Sight-Threatening Diabetic
Retinopathy and of Progression by 2 (or More) and 3 (or More) Steps on the Liverpool Diabetic Eye Study Scale in the Worse Eye of
Subjects in the Malawi Diabetic Retinopathy 24-Month Cohort Study and No Retinopathy at Baseline
T
Any Retinopathy Level 30 Level 40
N n Cumulative Incidence 95% CI N n Cumulative Incidence 95% CI N n Cumulative Incidence 95% CI
1 177 18 10.8% 6.1e15.5 177 6 3.6% 0.8e6.4 177 0 0% e
2 138 40 38.0% 30.2e45.8 150 3 5.6% 1.9e9.3 156 1 0.7% 0e2.0
T
STDR* 2D Step Progression 3D Step Progression
N n Cumulative Incidence 95% CI N n Cumulative Incidence 95% CI N n Cumulative Incidence 95% CI
1 174 0 0% e 177 8 4.8% 1.6e8.1 177 2 1.2% 0e2.9
2 154 4 2.7% 0.1e5.3 148 13 13.7% 8.2e19.3 154 1 1.9% 0e4.1
CI ¼ conﬁdence interval; N ¼ number entering time interval; n ¼ new cases diagnosed during year; STDR ¼ sight-threatening diabetic retinopathy; T ¼
time from recruitment (years).
*Patients with STDR at baseline were omitted from analysis.
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(level 20) was approximately 3 times (2.7% vs. estimates
between 0.5% and 0.8%2,23e25) and 2.5 times higher (27.3%
vs. estimates between 6.425 and 11.2%2), respectively.
Differences between our study and recent European work
are likely to reﬂect disparities in diabetic care, ethnicity,
access to health services, and presence of comorbidities. The
high crude mortality rate (8% over 2 years) among our
cohort is comparable to data from Tanzania. In a prospective
cohort study, McLarty et al26 reported 5-year mortality of
40.5% among those with insulin-dependent diabetes and
19.0% among subjects with non-insulin-dependent diabetes.
In contrast, the UK Prospective Diabetes Study27 reported
all-cause mortality across all study participants at a mean
of 10.0 years’ follow-up to be 17.9%. In the more recentFigure 1. Incidence at 2 years of sight-threatening diabetic retinopathy
(STDR) and proliferative diabetic retinopathy (PDR) (level 60þ) and of 2
(or more) step and 3 (or more) step progression on the Liverpool Diabetic
Eye Study (LDES) scale for subjects in the Malawi Diabetic Retinpathy
Study (MDRS) 24-month cohort with level 10 (n ¼ 177), level 20
(n ¼ 94), level 30 (n ¼ 25), level 40 (n ¼ 26), and level 50 (n ¼ 8)
retinopathy at baseline. Error bars indicate 95% CI. Classes STDR, PDR,
2-step progression, and 3-step progression are not exclusive, that is, a
single subject can develop STDR and PDR and progress by 2 steps on the
LDES scale.
1922Action to Control Cardiovascular Risk in Diabetes Study,28
follow-up all-cause mortality was 4.5% at a mean of 3.5
years. The association of death with STDR in the MDRS
suggests poor glycemic control and the presence of other
complications of diabetes. The high mortality indicates the
need for improved diabetes care in sub-Saharan Africa, but
in the context of our study, it is an important cause of data
censoring. As diabetes care improves, the prevalence of
retinopathy may (paradoxically) increase because of case
survival.
We report a negative association between DR progres-
sion and HIV infection, a novel ﬁnding. An important po-
tential confounder of this relationship is early diagnosis of
diabetes in HIV-positive subjects already attending health
facilities. Reduced progression may have been inﬂuenced by
high mortality in subjects with HIV and diabetes, removing
subjects whose DR would have otherwise progressed. This
possibility is supported by our sensitivity analysis: Pro-
gression of retinopathy was not associated, in univariate or
multivariate analysis, with a composite variable of 2-step
progression at 24 months or death during the study. Both
HIV infection and antiretroviral therapies are associated
with a vasculopathy that manifests as increased cardiovas-
cular and cerebrovascular risk.29,30 Low-grade proteinuria is
highly prevalent in HIV-positive patients taking antiretro-
viral therapy and is more common in persons with
concomitant diabetes.31 A real negative association between
HIV and DR is biologically plausible, but this ﬁnding
should be treated with caution.
In the MDRS 24-month cohort study, lower hemoglobin
was associated with the presence of STDR at baseline
(previously reported14) but not with the progression of DR.
Cross-sectional (but not cohort) studies have demonstrated
an association between the presence of DR and anemia in
India32e34 and China.35 Potential confounders of the
association between hemoglobin and retinopathy are
socioeconomic and nutritional status and decreased
erythropoietin production due to diabetic nephropathy. A
plausible mechanism for the relationship is impaired
oxygen delivery. Whether treatment of anemia reduces
diabetic microvascular complications is not known. Iron
Table 3. Risk Factors for Association of Progression of Diabetic
Retinopathy by 2 or More Steps on the Liverpool Diabetic Eye
Study Scale at 24 Months in the Malawi Diabetic Retinopathy
Study (n ¼ 293): Univariate and Multivariate Logistic Regression
OR 95% CI P Value
Univariate logistic regression
Duration of diabetes (yrs) 1.05 1.00e1.09 0.042*
Type 1 diabetes 2.09 0.89e4.89 0.090
Baseline grade of DR 1.48 1.23e1.76 0.001*
Scatter laser treatmenty 3.75 1.90e7.40 0.001*
Mean HbA1c (NGSP %) 1.28 1.13e1.44 0.001*
Mean sBP (mmHg) 1.00 0.99e1.02 0.68
log[Mean urine ACR] (mg/mmol) 1.28 1.07e1.52 0.005*
Mean hemoglobin (g/dl) 0.92 0.76e1.12 0.43
HIV positive 0.20 0.05e0.85 0.029*
Baseline LDL cholesterol (mmol/l) 0.99 0.72e1.34 0.92
Baseline HDL cholesterol (mmol/l) 2.24 0.98e5.14 0.057
Baseline triglycerides (mmol/l) 0.78 0.57e1.06 0.11
Sex (male) 1.04 0.58e1.87 0.89
Age (yrs) 0.99 0.97e1.01 0.49
Multivariate logistic regression
Mean HbA1c (NGSP %) 1.27 1.12e1.45 0.001*
Baseline grade of DR 1.39 1.02e1.91 0.040*
HIV positive 0.16 0.03e0.78 0.023*
Type 1 diabetes 2.27 0.87e5.89 0.094
Scatter laser treatmenty 1.45 0.43e4.88 0.54
ACR ¼ albumin-to-creatinine ratio; CI ¼ conﬁdence interval; DR ¼
diabetic retinopathy; HbA1c ¼ glycosylated hemoglobin; HDL ¼ high-
density lipoprotein; HIV ¼ human immunodeﬁciency virus; LDL ¼ low-
density lipoprotein; NGSP ¼ National Glycohemoglobin Standardisation
Program; OR ¼ odds ratio; sBP ¼ systolic blood pressure.
*Indicates statistical signiﬁcance.
yScatter laser treatment received any time between baseline and 24
months.
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diabetes: Both high iron level and iron supplementation
have been associated with gestational diabetes.36,37 To our
knowledge, no studies from Africa have reported longitu-
dinal VA data in subjects with diabetes. Although the
MDRS was an observational cohort study, subjects could
receive medical interventions with the potential for
improvement of vision, including laser photocoagulation
and cataract surgery. Without these interventions, visual loss
is likely to have been greater.
Study Limitations
We recognize the limitations of our clinic-based study.
Barriers to attendance include transportation costs,
competing economic tasks (planting and harvesting staple
crops), and ignorance of health services. Patients who do not
attend clinics may be less likely to be diagnosed with dia-
betes or to comply with therapy. Conversely, those with
established complications may be more likely to attend
clinics and participate in research studies. The MDRS
included few subjects with diet-controlled diabetes because
few of these attend the diabetic clinic.14 Although some
patients travel long distances to attend clinics, rural
subjects are likely to represent a selected subgroup of the
rural diabetic population.The prevalence of diabetes in Africa is increasing
rapidly, and there is an urgent need for service provision.
Future studies must provide an evidence base for preven-
tion, early detection, and management programs for DR in
the region. Our ﬁndings represent a baseline against which
the efﬁcacy and cost-effectiveness of such interventions can
be judged.
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philipburgess@doctors.org.uk.Pictures & PerspectivesGiant Eyelid Molluscum Contagiosum in a Child with AIDS
A 6-year-old boy presented with a 3-month history of multiple, pedunculated, nodules with a central umbilication (Fig 1A). A clinical
diagnosis of molluscum contagiosum was made and investigations revealed HIV infection with a CD4 count of 124/ml3. Highly active anti-
retroviral therapy (HAART) was initiated. The larger lesions were excised (Fig 1B). Characteristic eosinophilic intracytoplasmic inclusion
bodies were seen on histopathologic examination (Fig 1C; hematoxylin-eosin 40). The child is currently on maintenance therapy with
HAART with no recurrence of the lesions.
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